849833-56-3

Basic information

• Product Name: N'-HYDROXY-2-METHYLPROPANIMIDAMIDE
• Synonyms: (1Z)-N'-HYDROXY-2-METHYLPROPANIMIDAMIDE;UKRORGSYN-BB BBV-039207;N-Hydroxyisobutyrimidamide;(1Z)-N'-hydroxy-2-methylpropanimidamide(SALTDATA: FREE);N'-hydroxy-2-methyl-propionamidine;(Z)-N'-Hydroxyisobutyrimidamide
• CAS NO: 849833-56-3
• Molecular Formula: C₄H₁₀N₂O
• Molecular Weight: 102.14
• Mol File: 849833-56-3.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: N'-HYDROXY-2-METHYLPROPANIMIDAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N'-HYDROXY-2-METHYLPROPANIMIDAMIDE(849833-56-3)
• EPA Substance Registry System: N'-HYDROXY-2-METHYLPROPANIMIDAMIDE(849833-56-3)

Safety Data

• Hazardous Substances Data: 849833-56-3(Hazardous Substances Data)

Usage

Description

N'-HYDROXY-2-METHYLPROPANIMIDAMIDE, with the molecular formula C4H10N2O, is a hydroxamic acid derivative. This class of compounds is recognized for their chelating and metal-binding capabilities. N'-HYDROXY-2-METHYLPROPANIMIDAMIDE's ability to bind with metal ions makes it a significant entity in various applications.

Uses

Used in Chemical Manufacturing:
N'-HYDROXY-2-METHYLPROPANIMIDAMIDE is used as a metal chelator for removing metal ions from solutions. This application is particularly beneficial in chemical manufacturing processes where the removal of metal contaminants is essential for product purity and quality.
Used in Water Treatment:
In the water treatment industry, N'-HYDROXY-2-METHYLPROPANIMIDAMIDE is used as a metal chelator to purify water by sequestering metal ions. This contributes to the overall safety and cleanliness of the water supply.
Used in Medical Applications:
N'-HYDROXY-2-METHYLPROPANIMIDAMIDE is used as a chelating agent for treating metal toxicity in the body. Its ability to bind with metal ions aids in the detoxification process, providing a potential therapeutic intervention for heavy metal poisoning.
Used as a Pharmaceutical Intermediate:
In the pharmaceutical industry, N'-HYDROXY-2-METHYLPROPANIMIDAMIDE serves as an intermediate in the synthesis of other compounds. Its role in the production of various medications highlights its importance in drug development and manufacturing.

Upstream product

• 78-82-0 Isobutyronitrile 

Downstream Products

• 832714-37-1 1-[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-4-ol 
• 1229419-06-0 2-phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid {4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-phenyl}-amide 
• 1001398-17-9 4-({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}oxy)-1-[4-(methylsulfonyl)phenyl]-2,3-dihydro-1H-indole 
• 1588943-57-0 3-isopropyl-5-(4-((1R,2S)-2-((4-(methylsulfonyl)benzyloxy)methyl)cyclopropyl)piperidin-1-yl)-1,2,4-oxadiazole 
• 1415835-33-4 N-cyclopropyl-N-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-4-yl]-6-(4-methanesulfonyl-phenyl)-nicotinamide 
• 163719-70-8 Ethyl 3-isopropyl-1,2,4-oxadiazole-5-carboxylate 
• 1391081-19-8 1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-4-[5-(4-methanesulfonyl-phenyl)-2,3-dihydro-benzofuran-2-yl]-piperidine 
• 1309377-33-0 C₂₄H₂₄F₂N₆O₃ 
• 1035040-82-4 4-[(4-Chlorophenyl)methyl]-2-[((2R)-1-{2-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]ethyl}-2-pyrrolidinyl)methyl]-1(2H)-phthalazinone, hydrochloride 
• 1199-49-1 3-isopropyl-5-(trichloromethyl)-1,2,4-oxadiazole 
• 1196486-71-1 4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-cyclohexanone 
• 1163126-27-9 2-ethyl-N-(3-fluoro-4-(4-((3-isopropyl-[1,2,4]oxadiazol-5-yl)(phenyl)methyl)piperazin-1-yl)phenyl)butyramide 
• 1037793-31-9 1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-4-[4-(4-tetrazol-1-ylphenoxymethyl)thiazol-2-yl]piperidine 
• 35613-84-4 isobutyramide oxime 

Relevant articles and documents

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease(AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5- containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age- Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer' s Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson' s disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.

NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present invention relates to compounds of general formula I, wherein R1, LP, HetAr, Ar, and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.